A new oral antibiotic stubborn gonorrhea can be a success in the fight against infection, a sexually transmitted infection that health authorities have warned that it is difficult for treatment.

In a clinical trial, UTI drug gapotidasin approved infections in 93% of cases, as well as current standard treatment as well as according to the conclusions published in the Lancet.

Gonorrhea caused by bacterial nesaria gonorrhea, usually spreads through unsafe vagina, oral or anal sex. It is often settled in women due to the absence of symptoms.

However, if left untreated, it can increase infertility, chronic pelvic pain and HIV risk.

The study tested Gepotidacin (previously used for urinary tract infection) with direct gonorrhea on 628 participants. Half received two doses of oral gapotidasin, while the other was given an injection of saftrexone and an oral dose of the current dual therapy azithromycin.

The results showed that the bullet was overall equally effective: 93% of the participants who took gapotidasin were fixed, while in the standard group compared to 91%.

Gepotidasin was already being used to treat urinary tract infections, but this is the first time it has shown success against gonorrhea. It works differently with current antibiotics by blocking the DNA replication of bacteria, making it effective in cases with known resistance.

Researchers found that the new drug was 100% effective against rectal gonorrhea, although it showed less efficacy for throat infection (78%) compared to 94% with standard treatment. Further data is required, especially for pharyngeal infection and in broad population.

Some people experienced mild issues such as nausea or diarrhea, but nothing was said to be serious.

Testing results come as the UK faces an increase in antibiotic-resistant gonorrhea. According to the UK Health Security Agency (UKHSA), 17 cases of safetrexone-resistant gonorrhea were reported from January 2024 to March 2025, including nine which were largely drug-resistant.

Dr. of Ukhsa Katie Sink warned that it was difficult to treat infection and urged people to test with new or casual partners. Experts also warned that the use of gapotidasin should be carefully monitored to prevent future resistance.

Therefore, while Gepotidacin brings hope, experts are particularly careful for those who cannot take injections or who have infections that do not respond to current drugs. If this new treatment is used, resistance can re -manufacture.

This is why it is important to develop STI prevention, regular testing, and even more treatment options.